Zepbound: FDA-Approved Weight Loss Medication

What Is Zepbound?

Zepbound is a brand-name prescription medication manufactured by Eli Lilly. Its active ingredient is tirzepatide — the same molecule found in Mounjaro, but FDA-approved specifically for chronic weight management rather than type 2 diabetes. Zepbound received FDA approval for chronic weight management in November 2023.

What distinguishes tirzepatide from semaglutide-based medications like Wegovy is its dual mechanism. Tirzepatide activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Both GLP-1 and GIP are naturally occurring gut hormones released after eating. Activating both receptor types simultaneously is believed to produce a more pronounced effect on appetite reduction and metabolic regulation than activating GLP-1 receptors alone.

FDA Approval and Eligibility

Zepbound is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults who meet one of the following criteria:

• Body mass index (BMI) of 30 kg/m² or greater (obesity), or
• BMI of 27 kg/m² or greater (overweight) with at least one weight-related health condition such as type 2 diabetes, high blood pressure, or dyslipidemia

Eligibility is determined by a licensed clinician through a full medical evaluation. Contraindications include personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and active pancreatitis. Only a licensed clinician can evaluate whether Zepbound is appropriate for your situation.

How Zepbound Works: Dual GIP + GLP-1 Action

Tirzepatide is described as a "twincretin" because it activates both incretin hormone receptors — GLP-1 and GIP. Each receptor plays a role in metabolic regulation:

• GLP-1 receptor activation: Reduces appetite, slows gastric emptying, promotes satiety, and stimulates insulin secretion in a glucose-dependent manner.
• GIP receptor activation: May enhance the effects of GLP-1 receptor activation, improve insulin sensitivity, and have additional effects on fat metabolism and energy homeostasis. The precise additive contribution of GIP agonism is still being studied.

The clinical result is an appetite-suppressing and metabolic effect that in clinical trials produced greater average weight loss than semaglutide alone — though direct head-to-head trials between Zepbound and Wegovy in the weight management setting are limited.

Zepbound Dosing Schedule

Zepbound is administered as a once-weekly subcutaneous injection. The dose is escalated gradually to allow the body to adjust and minimize gastrointestinal side effects. The maintenance doses are 10 mg or 15 mg weekly, based on clinical response and tolerability.

Typical dose escalation (as per prescribing information):

• Weeks 1–4: 2.5 mg once weekly
• Weeks 5–8: 5.0 mg once weekly
• Weeks 9–12: 7.5 mg once weekly (if tolerating and clinically appropriate)
• Weeks 13–16: 10 mg once weekly
• Week 17 onward: 10 mg or 15 mg weekly (maintenance)

Dosing decisions are made by the prescribing clinician and may be adjusted based on your clinical response and tolerability.

Clinical Data: SURMOUNT Trials

Zepbound's FDA approval is supported by data from the SURMOUNT clinical trial program:

• SURMOUNT-1: Adults without diabetes — average body weight reduction of approximately 20.9% at the highest dose (15 mg) over 72 weeks, compared to 3.1% with placebo. Results at the 10 mg dose were approximately 19.5%.
• SURMOUNT-2: Adults with type 2 diabetes — average weight reduction of approximately 15.7% at 15 mg vs. 3.3% with placebo.
• SURMOUNT-3 and 4: Examined weight loss following an intensive lifestyle intervention lead-in phase and the effects of continued vs. discontinued treatment.

These are clinical trial averages. Individual results vary based on many factors. Discuss realistic expectations with your licensed clinician.

Zepbound vs. Mounjaro: Key Differences

Zepbound and Mounjaro share the same active ingredient — tirzepatide — but they are different FDA-approved products with different indications:

Zepbound Cost and Insurance

Zepbound's approximate list price is $1,000–$1,100 per month before insurance or savings programs. Eli Lilly has also offered self-pay vial options at lower price points — verify current availability and pricing directly with Lilly or a licensed pharmacy.

Insurance coverage for Zepbound varies. The same challenges apply as with Wegovy — weight management medications are inconsistently covered. Eli Lilly offers a savings program for eligible commercially insured patients. See our Zepbound cost guide and GLP-1 cost guide for full details.